Actinium Pharmaceuticals Company Leadership
| ATNM Stock | USD 1.55 0.14 9.93% |
Actinium Pharmaceuticals employs about 37 people. The company is managed by 18 executives with a total tenure of roughly 6 years, averaging almost 0.0 years of service per executive, having 2.06 employees per reported executive. Analysis of Actinium Pharmaceuticals' management performance can provide insight into the firm performance.
Actinium |
Actinium Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.3285) % which means that it has lost $0.3285 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0005) %, meaning that it created substantial loss on money invested by shareholders. Actinium Pharmaceuticals' management efficiency ratios could be used to measure how well Actinium Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of March 2025, Return On Tangible Assets is likely to grow to -0.51. In addition to that, Return On Capital Employed is likely to grow to -0.78. At this time, Actinium Pharmaceuticals' Total Assets are very stable compared to the past year. As of the 25th of March 2025, Total Current Assets is likely to grow to about 94.5 M, while Other Assets are likely to drop 1.09.As of the 25th of March 2025, Common Stock Shares Outstanding is likely to grow to about 32.1 M, while Net Loss is likely to drop (31.2 M).
Actinium Pharmaceuticals Workforce Comparison
Actinium Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 4,653. Actinium Pharmaceuticals maintains roughly 37.0 in number of employees contributing less than 1% to equities under Health Care industry.
Actinium Pharmaceuticals Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Actinium Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Actinium Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Actinium Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Seth Sandesh over three weeks ago Acquisition by Seth Sandesh of 8125 shares of Actinium Pharmaceuticals at 0.6 subject to Rule 16b-3 | ||
Almenoff June Sherie over three months ago Insider Trading | ||
Nicholson, C. David over six months ago Acquisition by Nicholson, C. David of 70311 shares of Actinium Pharmaceuticals at 5.0 subject to Rule 16b-3 | ||
Mark Berger over six months ago Acquisition by Mark Berger of 400000 shares of Actinium Pharmaceuticals at 0.232 subject to Rule 16b-3 | ||
C Nicholson over a year ago Acquisition by C Nicholson of 70311 shares of Actinium Pharmaceuticals subject to Rule 16b-3 |
Actinium Pharmaceuticals Notable Stakeholders
An Actinium Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Actinium Pharmaceuticals often face trade-offs trying to please all of them. Actinium Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Actinium Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| MS MBA | Chairman CEO | Profile | |
| Mamata Gokhale | Vice President Global Head of Regulatory Affairs | Profile | |
| Steven BS | CFO Secretary | Profile | |
| Sunitha Lakshminarayanan | Head VP | Profile | |
| Elaina Haeuber | VP Operations | Profile | |
| Bernie PMP | Executive Management | Profile | |
| Qing Liang | VP Sciences | Profile | |
| Madhuri MD | Vice Therapy | Profile | |
| Lynn MBA | Chief Officer | Profile | |
| Paul Esq | Vice Counsel | Profile | |
| Jenny Hsieh | Chief Officer | Profile | |
| Dr MS | VP Operations | Profile | |
| Arun Swaminathan | Chief Officer | Profile | |
| Caroline Yarbrough | Chief Officer | Profile | |
| J Simeon | Executive Assurance | Profile | |
| David Gould | Senior Affairs | Profile | |
| MBA MS | Chairman CEO | Profile | |
| Avinash MD | Chief Officer | Profile |
About Actinium Pharmaceuticals Management Performance
The success or failure of an entity such as Actinium Pharmaceuticals often depends on how effective the management is. Actinium Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Actinium management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Actinium management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.54) | (0.51) | |
| Return On Capital Employed | (0.82) | (0.78) | |
| Return On Assets | (0.54) | (0.51) | |
| Return On Equity | (1.54) | (1.47) |
Actinium Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Actinium Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Actinium Pharmaceuticals within its industry.Actinium Pharmaceuticals Manpower Efficiency
Return on Actinium Pharmaceuticals Manpower
| Revenue Per Employee | 2.2K | |
| Revenue Per Executive | 4.5K | |
| Net Loss Per Employee | 1.3M | |
| Net Loss Per Executive | 2.7M | |
| Working Capital Per Employee | 1.9M | |
| Working Capital Per Executive | 3.9M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Actinium Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Actinium Pharmaceuticals. If investors know Actinium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Actinium Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.39) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Actinium Pharmaceuticals is measured differently than its book value, which is the value of Actinium that is recorded on the company's balance sheet. Investors also form their own opinion of Actinium Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Actinium Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Actinium Pharmaceuticals' market value can be influenced by many factors that don't directly affect Actinium Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Actinium Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Actinium Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Actinium Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.